Key facts
- This page summarizes Patrick D. Spangler's Form 4 filing for OptimizeRx Corp (OPRX).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2023, 09:33.
Patrick D. Spangler - 07 Jun 2023 Form 4 Insider Report for OptimizeRx Corp (OPRX)
- Reporting relationship
- Director
- Issuer ticker
- OPRX
- Reported as of
- 07 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2023, 09:33:33 UTC
- Prior SEC filing
- 03 Apr 2023
- Next SEC filing
- 11 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marion Odence-Ford, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick D. Spangler filed Form 4 for OptimizeRx Corp (OPRX) on 18 Aug 2023.
Change
- Previous filing in this sequence was filed on 03 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OPRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +4,637
- Change %
- +27%
- Price
- $0.000000
- Shares after
- 22,120
- Date
- 07 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OPRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,637
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 07 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,637
- Exercise price
- Footnotes
- F1, F2
OPRX
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +10,061
- Change %
- Price
- $0.000000
- Shares after
- 10,061
- Date
- 07 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,061
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023.
Footnote F3
Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.
Footnote F4
The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders.
SEC remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.